Additionally, PTK6 exhibits a crucial association with the immune microenvironment, and inhibition of PTK6 leads to up-regulation of PD-L1 expression, In conclusion, PTK6 may be a novel potential biomarker for LUAD, and may be synergistic with immunotherapy, thereby enhancing therapeutic efficacy and inhibiting tumor progression. Here, PTK6 is linked to neoplasm.